HemoSense and ZyCare Partner with Pima Heart to Utilize Web-Based Warfarin Patient Management System for INRatio
04 5์ 2007 - 8:00PM
Business Wire
HemoSense, Inc. (AMEX:HEM) and ZyCare, Inc. today announced that
Pima Heart, a cardiology practice that provides medical and
surgical services in southern Arizona, will use ZyCare๏ฟฝs CoagCare๏ฟฝ
software management system to remotely manage Pima Heart patients
who wish to use HemoSense๏ฟฝs portable INRatio๏ฟฝ PT/INR monitoring
system for self-testing. CoagCare will also be used as the
point-of-care anticoagulation management software in all seven Pima
Heart locations. After performing a PT/INR test with the INRatio
system, patients use a standard Internet browser to input INR test
results and information about symptoms and illness into the
CoagCare system. CoagCare then provides automated, patient specific
warfarin dosage adjustments based on physician-prescribed
algorithms. Test results are immediately available to healthcare
providers, and patients who report out of range INR values,
hemorrhagic, or thromboembolic symptoms, are prioritized for
physician review. CoagCare is the only U.S. Food and Drug
Administration (FDA) cleared, HIPAA compatible remote INR test
reporting and dosage management system for patients on oral
anticoagulant therapy. ๏ฟฝPima Heart currently utilizes our INRatio
system in its anticoagulation clinics and the expansion of this
relationship is a testament to the technical capabilities and
versatility of our INRatio product, as well as the strength of
ZyCare๏ฟฝs Web-based management tools,๏ฟฝ said Timothy Still, executive
VP and chief commercial officer of HemoSense. ๏ฟฝOf the millions of
people taking warfarin there is a tremendous opportunity to improve
their care and lives through more frequent testing, better
monitoring and education,๏ฟฝ said Ted Ranney, Pima Heart chief
executive officer. ๏ฟฝWe believe that the promotion of home-testing
and offering additional management tools assist in affording
patients this opportunity. We are excited to offer this new service
to our patients.๏ฟฝ Pima Heart currently manages more than 1,000
patients taking warfarin. By using the INRatio and instituting the
CoagCare system, Pima Heart expects to be able to reduce the number
of patient visits to its clinics, while effectively managing
patient self-testers, so that it can focus on the critical patients
who need the most attention. ๏ฟฝWe are delighted with the expansion
of our relationship with HemoSense, and our new relationship with a
patient-focused organization such as Pima Heart, in order to bring
the benefits of CoagCare and 'supervised self-management'๏ฟฝ to the
patients of southern Arizona,๏ฟฝ said Sandra Cummings, president of
ZyCare. About Pima Heart Pima Heart, of Tucson, Ariz., was founded
in 1981 and today is the largest cardiovascular practice in
southern Arizona, with 25 cardiologists, eight nurse practitioners
and a highly trained support staff serving multiple communities
throughout southern Arizona. Pima Heart is a team dedicated to
providing comprehensive cardiac care, with a commitment to reducing
the incidence, prevalence and mortality of cardiovascular disease
while providing quality care and personal service. About ZyCare
ZyCare develops medical information technology solutions that
increase productivity for healthcare professionals in the
management of chronic diseases while simultaneously improving
quality of patient care and reducing costs. ZyCare utilizes
innovative web-based ๏ฟฝdirect-to-patient expert systems๏ฟฝ๏ฟฝ to
automate much of the routine decision making involved in managing
patients remotely. ZyCare's solutions directly involve patients in
the information gathering that drives automated treatment
recommendations, while giving physicians a vehicle to closely
monitor their patient๏ฟฝs progress without time consuming telephone
calls and faxes. This approach allows the healthcare system to
cost-effectively take advantage of new home monitoring devices for
chronic conditions, while giving patients more control over their
own condition. ZyCare's technology is protected by patents issued
in the United States, Canada, Europe and Australia. For more
information, visit www.coagcare.com. About HemoSense HemoSense is a
point-of-care diagnostic healthcare company that develops,
manufactures and markets easy-to-use, handheld blood coagulation
systems for monitoring patients taking warfarin. The HemoSense
INRatio(R) system, used by healthcare professionals and patients
themselves, consists of a small monitor and disposable test strips.
It provides accurate and convenient measurement of blood clotting
time, or PT/INR values. Routine measurements of PT/INR are
necessary for the safe and effective management of the patient's
warfarin dosing. INRatio is sold in the United States and
internationally. For more information, visit www.hemosense.com.
HemoSense๏ฟฝ and INRatio๏ฟฝ are registered trademarks of HemoSense,
Inc. CoagCare๏ฟฝ and ZyCare๏ฟฝ are registered trademarks of ZyCare,
Inc. "Supervised Self-Management" and "Direct-to-Patient Expert
Systems" are trademarks of ZyCare, Inc.
Hemosense (AMEX:HEM)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 10์(10) 2024 ์ผ๋ก 11์(11) 2024
Hemosense (AMEX:HEM)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 11์(11) 2023 ์ผ๋ก 11์(11) 2024
Hemosense (์๋ฉ๋ฆฌ์นด ์ฆ๊ถ๊ฑฐ๋์)์ ์ค์๊ฐ ๋ด์ค: ์ต๊ทผ ๊ธฐ์ฌ 0
More HemoSense, Inc. News Articles